25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BIOCRYST PHARM (BO1.SG)
Buy, Hold or Sell?

Let's analyze BIOCRYST PHARM (BO1.SG) together

I guess you are interested in BIOCRYST PHARM (BO1.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BIOCRYST PHARM (BO1.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BIOCRYST PHARM (BO1.SG)

I send you an email if I find something interesting about BIOCRYST PHARM (BO1.SG).

1. Quick Overview

1.1. Quick analysis of BIOCRYST PHARM (BO1.SG) (30 sec.)










1.2. What can you expect buying and holding a share of BIOCRYST PHARM (BO1.SG)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€-2.10
Expected worth in 1 year
€-2.17
How sure are you?
23.8%

+ What do you gain per year?

Total Gains per Share
€-0.06
Return On Investment
-0.9%

For what price can you sell your share?

Current Price per Share
€7.04
Expected price per share
€6.438 - €9.006
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of BIOCRYST PHARM (BO1.SG) (5 min.)




Live pricePrice per Share (EOD)
€7.04
Intrinsic Value Per Share
€2.80 - €3.60
Total Value Per Share
€0.70 - €1.50

2.2. Growth of BIOCRYST PHARM (BO1.SG) (5 min.)




Is BIOCRYST PHARM (BO1.SG) growing?

Current yearPrevious yearGrowGrow %
How rich?-$475.9m-$395.8m-$78.1m-16.5%

How much money is BIOCRYST PHARM (BO1.SG) making?

Current yearPrevious yearGrowGrow %
Making money-$22.2m-$56.6m$34.4m154.9%
Net Profit Margin-20.5%-69.2%--

How much money comes from the company's main activities?

2.3. Financial Health of BIOCRYST PHARM (BO1.SG) (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of BIOCRYST PHARM (BO1.SG)?

Welcome investor! BIOCRYST PHARM (BO1.SG)'s management wants to use your money to grow the business. In return you get a share of BIOCRYST PHARM (BO1.SG).

First you should know what it really means to hold a share of BIOCRYST PHARM (BO1.SG). And how you can make/lose money.

Speculation

The Price per Share of BIOCRYST PHARM (BO1.SG) is €7.036. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BIOCRYST PHARM (BO1.SG).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BIOCRYST PHARM (BO1.SG), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €-2.10. Based on the TTM, the Book Value Change Per Share is €-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BIOCRYST PHARM (BO1.SG).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.13-1.8%-0.11-1.5%-0.29-4.2%-0.25-3.6%-0.21-3.0%
Usd Book Value Change Per Share-0.02-0.3%-0.02-0.2%-0.16-2.3%-0.13-1.8%-0.11-1.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-0.3%-0.02-0.2%-0.16-2.3%-0.13-1.8%-0.11-1.5%
Usd Price Per Share7.92-6.65-7.13-8.68-7.35-
Price to Earnings Ratio-15.41--18.83--6.58--11.16--11.09-
Price-to-Total Gains Ratio-398.25-195.23--65.00-7.07-7.29-
Price to Book Ratio-3.47--2.91--3.56--4.92--3.60-
Price-to-Total Gains Ratio-398.25-195.23--65.00-7.07-7.29-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.637578
Number of shares130
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.02-0.13
Usd Total Gains Per Share-0.02-0.13
Gains per Quarter (130 shares)-2.22-16.45
Gains per Year (130 shares)-8.89-65.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-190-66-76
20-18-280-132-142
30-27-370-197-208
40-36-460-263-274
50-44-550-329-340
60-53-640-395-406
70-62-730-461-472
80-71-820-526-538
90-80-910-592-604
100-89-1000-658-670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%4.016.00.020.0%5.016.00.023.8%5.016.00.023.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%4.016.00.020.0%5.016.00.023.8%5.016.00.023.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BIOCRYST PHARM (BO1.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.018-0.016-14%-0.149+712%-0.117+536%-0.100+446%
Book Value Per Share---2.102-2.108+0%-1.881-11%-1.110-47%-0.915-56%
Current Ratio--2.6312.989-12%5.018-48%3.744-30%3.368-22%
Debt To Asset Ratio--1.9701.987-1%1.761+12%1.478+33%1.405+40%
Debt To Equity Ratio----0%-0%2.124-100%2.141-100%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--631744807.896389954228.674+62%422771753.500+49%894050180.528-29%865275855.931-27%
Eps---0.118-0.099-17%-0.270+128%-0.231+95%-0.193+63%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--1.3030.890+46%1.459-11%10.835-88%10.414-87%
Free Cash Flow Per Share---0.026-0.059+128%-0.117+352%-0.150+475%-0.145+459%
Free Cash Flow To Equity Per Share---0.044-0.066+50%-0.078+78%0.048-192%0.065-168%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.598--------
Intrinsic Value_10Y_min--2.801--------
Intrinsic Value_1Y_max---0.380--------
Intrinsic Value_1Y_min---0.374--------
Intrinsic Value_3Y_max---0.578--------
Intrinsic Value_3Y_min---0.563--------
Intrinsic Value_5Y_max---0.095--------
Intrinsic Value_5Y_min---0.137--------
Market Cap--1521950112.6961269298355.174+20%1266365259.500+20%1500257724.008+1%1267548995.006+20%
Net Profit Margin---0.204-0.205+1%-0.692+239%-2.867+1307%-4.577+2147%
Operating Margin----0%-0%-2.0050%-3.6670%
Operating Ratio--1.0811.037+4%1.329-19%3.599-70%5.217-79%
Pb Ratio-3.347+4%-3.471-2.908-16%-3.555+2%-4.916+42%-3.605+4%
Pe Ratio-14.861+4%-15.415-18.831+22%-6.582-57%-11.155-28%-11.090-28%
Price Per Share7.036-4%7.2986.124+19%6.567+11%7.993-9%6.773+8%
Price To Free Cash Flow Ratio-67.630+4%-70.149-58.860-16%-18.642-73%-23.700-66%-20.197-71%
Price To Total Gains Ratio-383.954+4%-398.252195.227-304%-64.998-84%7.069-5734%7.294-5560%
Quick Ratio--1.8412.118-13%3.104-41%1.527+21%1.401+31%
Return On Assets---0.055-0.046-15%-0.109+99%-0.131+139%-0.149+173%
Return On Equity----0%-0%-0.6090%-0.5680%
Total Gains Per Share---0.018-0.016-14%-0.149+712%-0.117+536%-0.100+446%
Usd Book Value---475916200.068-474049769.8760%-395863694.144-17%-236743645.457-50%-196856678.952-59%
Usd Book Value Change Per Share---0.020-0.017-14%-0.161+712%-0.127+536%-0.109+446%
Usd Book Value Per Share---2.282-2.288+0%-2.042-11%-1.205-47%-0.994-56%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--685758988.971423295315.226+62%458918738.424+49%970491470.963-29%939256941.613-27%
Usd Eps---0.128-0.107-17%-0.293+128%-0.251+95%-0.210+63%
Usd Free Cash Flow---5887779.789-13285503.104+126%-24326340.161+313%-29795185.618+406%-28576139.546+385%
Usd Free Cash Flow Per Share---0.028-0.064+128%-0.128+352%-0.162+475%-0.158+459%
Usd Free Cash Flow To Equity Per Share---0.048-0.071+50%-0.084+78%0.052-192%0.070-168%
Usd Market Cap--1652076847.3321377823364.541+20%1374639489.187+20%1628529759.410+1%1375924434.079+20%
Usd Price Per Share7.638-4%7.9226.647+19%7.128+11%8.676-9%7.352+8%
Usd Profit---26793997.867-22219418.963-17%-56632631.860+111%-46468862.000+73%-43261256.968+61%
Usd Revenue--131529080.628112673785.843+17%82849901.298+59%61394353.765+114%53196677.037+147%
Usd Total Gains Per Share---0.020-0.017-14%-0.161+712%-0.127+536%-0.109+446%
 EOD+2 -4MRQTTM+18 -15YOY+23 -105Y+21 -1310Y+21 -13

3.3 Fundamental Score

Let's check the fundamental score of BIOCRYST PHARM (BO1.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-14.861
Price to Book Ratio (EOD)Between0-1-3.347
Net Profit Margin (MRQ)Greater than0-0.204
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.841
Current Ratio (MRQ)Greater than12.631
Debt to Asset Ratio (MRQ)Less than11.970
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.055
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of BIOCRYST PHARM (BO1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose6.910
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About BIOCRYST PHARM (BO1.SG)

  • Other
  • 0

There is no Profile data available for BO1.SG.

Fundamental data was last updated by Penke on 2025-03-11 19:34:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit BIOCRYST PHARM (BO1.SG) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • A Net Profit Margin of -20.4% means that €-0.20 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is -20.4%. The company is making a huge loss. -2
  • The TTM is -20.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-20.4%TTM-20.5%+0.2%
TTM-20.5%YOY-69.2%+48.6%
TTM-20.5%5Y-286.7%+266.2%
5Y-286.7%10Y-457.7%+171.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.4%5.6%-26.0%
TTM-20.5%5.9%-26.4%
YOY-69.2%6.1%-75.3%
5Y-286.7%6.2%-292.9%
10Y-457.7%6.1%-463.8%
4.3.1.2. Return on Assets

Shows how efficient BIOCRYST PHARM (BO1.SG) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • -5.5% Return on Assets means that BIOCRYST PHARM (BO1.SG) generated €-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is -5.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-4.6%-0.8%
TTM-4.6%YOY-10.9%+6.2%
TTM-4.6%5Y-13.1%+8.4%
5Y-13.1%10Y-14.9%+1.9%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%1.3%-6.8%
TTM-4.6%1.1%-5.7%
YOY-10.9%1.3%-12.2%
5Y-13.1%1.3%-14.4%
10Y-14.9%1.3%-16.2%
4.3.1.3. Return on Equity

Shows how efficient BIOCRYST PHARM (BO1.SG) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • 0.0% Return on Equity means BIOCRYST PHARM (BO1.SG) generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-60.9%+60.9%
5Y-60.9%10Y-56.8%-4.1%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.7%-3.7%
TTM-3.4%-3.4%
YOY-3.9%-3.9%
5Y-60.9%3.9%-64.8%
10Y-56.8%3.8%-60.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BIOCRYST PHARM (BO1.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient BIOCRYST PHARM (BO1.SG) is operating .

  • Measures how much profit BIOCRYST PHARM (BO1.SG) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-200.5%+200.5%
5Y-200.5%10Y-366.7%+166.1%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-12.7%
TTM-8.2%-8.2%
YOY-7.8%-7.8%
5Y-200.5%4.4%-204.9%
10Y-366.7%6.8%-373.5%
4.3.2.2. Operating Ratio

Measures how efficient BIOCRYST PHARM (BO1.SG) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 1.08 means that the operating costs are €1.08 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 1.081. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.037. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.081TTM1.037+0.043
TTM1.037YOY1.329-0.291
TTM1.0375Y3.599-2.562
5Y3.59910Y5.217-1.618
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0811.313-0.232
TTM1.0371.355-0.318
YOY1.3291.375-0.046
5Y3.5991.324+2.275
10Y5.2171.381+3.836
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BIOCRYST PHARM (BO1.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if BIOCRYST PHARM (BO1.SG) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 2.63 means the company has €2.63 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 2.631. The company is able to pay all its short-term debts. +1
  • The TTM is 2.989. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.631TTM2.989-0.358
TTM2.989YOY5.018-2.029
TTM2.9895Y3.744-0.755
5Y3.74410Y3.368+0.376
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6311.426+1.205
TTM2.9891.416+1.573
YOY5.0181.538+3.480
5Y3.7441.562+2.182
10Y3.3681.496+1.872
4.4.3.2. Quick Ratio

Measures if BIOCRYST PHARM (BO1.SG) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • A Quick Ratio of 1.84 means the company can pay off €1.84 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 1.841. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.118. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.841TTM2.118-0.277
TTM2.118YOY3.104-0.986
TTM2.1185Y1.527+0.591
5Y1.52710Y1.401+0.127
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8410.531+1.310
TTM2.1180.553+1.565
YOY3.1040.603+2.501
5Y1.5270.606+0.921
10Y1.4010.609+0.792
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BIOCRYST PHARM (BO1.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of BIOCRYST PHARM (BO1.SG) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to Other industry mean.
  • A Debt to Asset Ratio of 1.97 means that BIOCRYST PHARM (BO1.SG) assets are financed with 197.0% credit (debt) and the remaining percentage (100% - 197.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 1.970. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.987. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.970TTM1.987-0.017
TTM1.987YOY1.761+0.226
TTM1.9875Y1.478+0.509
5Y1.47810Y1.405+0.073
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9700.520+1.450
TTM1.9870.529+1.458
YOY1.7610.523+1.238
5Y1.4780.555+0.923
10Y1.4050.564+0.841
4.5.4.2. Debt to Equity Ratio

Measures if BIOCRYST PHARM (BO1.SG) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y2.124-2.124
5Y2.12410Y2.141-0.017
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.095-1.095
TTM-1.128-1.128
YOY-1.155-1.155
5Y2.1241.338+0.786
10Y2.1411.429+0.712
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings BIOCRYST PHARM (BO1.SG) generates.

  • Above 15 is considered overpriced but always compare BIOCRYST PHARM (BO1.SG) to the Other industry mean.
  • A PE ratio of -15.41 means the investor is paying €-15.41 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The EOD is -14.861. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.415. Based on the earnings, the company is expensive. -2
  • The TTM is -18.831. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.861MRQ-15.415+0.553
MRQ-15.415TTM-18.831+3.416
TTM-18.831YOY-6.582-12.249
TTM-18.8315Y-11.155-7.675
5Y-11.15510Y-11.090-0.065
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-14.86114.089-28.950
MRQ-15.41513.537-28.952
TTM-18.83112.493-31.324
YOY-6.58211.191-17.773
5Y-11.15512.976-24.131
10Y-11.09013.175-24.265
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The EOD is -67.630. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -70.149. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -58.860. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-67.630MRQ-70.149+2.518
MRQ-70.149TTM-58.860-11.288
TTM-58.860YOY-18.642-40.219
TTM-58.8605Y-23.700-35.161
5Y-23.70010Y-20.197-3.503
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-67.6308.643-76.273
MRQ-70.1498.169-78.318
TTM-58.8607.139-65.999
YOY-18.6425.896-24.538
5Y-23.7003.220-26.920
10Y-20.1973.714-23.911
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of BIOCRYST PHARM (BO1.SG) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of -3.47 means the investor is paying €-3.47 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BIOCRYST PHARM (BO1.SG):

  • The EOD is -3.347. Based on the equity, the company is expensive. -2
  • The MRQ is -3.471. Based on the equity, the company is expensive. -2
  • The TTM is -2.908. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.347MRQ-3.471+0.125
MRQ-3.471TTM-2.908-0.563
TTM-2.908YOY-3.555+0.647
TTM-2.9085Y-4.916+2.008
5Y-4.91610Y-3.605-1.311
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-3.3471.532-4.879
MRQ-3.4711.404-4.875
TTM-2.9081.428-4.336
YOY-3.5551.405-4.960
5Y-4.9161.718-6.634
10Y-3.6051.715-5.320
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets490,420
Total Liabilities966,354
Total Stockholder Equity-475,934
 As reported
Total Liabilities 966,354
Total Stockholder Equity+ -475,934
Total Assets = 490,420

Assets

Total Assets490,420
Total Current Assets421,968
Long-term Assets68,452
Total Current Assets
Cash And Cash Equivalents 104,713
Short-term Investments 216,137
Net Receivables 79,069
Inventory 8,087
Other Current Assets 13,752
Total Current Assets  (as reported)421,968
Total Current Assets  (calculated)421,758
+/- 210
Long-term Assets
Property Plant Equipment 19,785
Long Term Investments 20,323
Long-term Assets Other 28,344
Long-term Assets  (as reported)68,452
Long-term Assets  (calculated)68,452
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities160,384
Long-term Liabilities805,970
Total Stockholder Equity-475,934
Total Current Liabilities
Accounts payable 11,644
Other Current Liabilities 32,676
Total Current Liabilities  (as reported)160,384
Total Current Liabilities  (calculated)44,320
+/- 116,064
Long-term Liabilities
Long term Debt 795,922
Capital Lease Obligations Min Short Term Debt12,820
Long-term Liabilities  (as reported)805,970
Long-term Liabilities  (calculated)808,742
+/- 2,772
Total Stockholder Equity
Total Stockholder Equity (as reported)-475,934
Total Stockholder Equity (calculated)0
+/- 475,934
Other
Capital Stock2,085
Common Stock Shares Outstanding 208,543
Net Debt 691,209
Net Invested Capital 319,988
Net Working Capital 261,584
Property Plant and Equipment Gross 32,134



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
142,338
116,344
90,500
175,282
136,589
214,706
176,226
334,715
284,431
277,284
265,763
588,151
527,720
510,538
558,594
550,000
509,737
529,885
522,924
516,960
467,892
472,419
491,254
490,420
490,420491,254472,419467,892516,960522,924529,885509,737550,000558,594510,538527,720588,151265,763277,284284,431334,715176,226214,706136,589175,28290,500116,344142,338
   > Total Current Assets 
117,649
103,719
78,803
164,345
125,508
203,837
162,436
323,800
273,771
265,802
252,743
566,136
511,714
494,853
509,001
516,500
490,883
511,056
502,466
495,966
447,100
363,457
427,125
421,968
421,968427,125363,457447,100495,966502,466511,056490,883516,500509,001494,853511,714566,136252,743265,802273,771323,800162,436203,837125,508164,34578,803103,719117,649
       Cash And Cash Equivalents 
34,804
30,760
29,903
114,172
101,873
173,468
96,492
272,127
226,902
210,314
199,597
504,389
395,504
272,571
246,899
304,767
155,136
146,215
150,905
110,643
84,333
78,410
96,841
104,713
104,71396,84178,41084,333110,643150,905146,215155,136304,767246,899272,571395,504504,389199,597210,314226,902272,12796,492173,468101,873114,17229,90330,76034,804
       Short-term Investments 
72,753
61,387
38,532
22,054
11,185
15,935
46,827
28,239
13,454
8,114
0
3,212
47,964
144,912
179,959
119,543
243,022
264,455
246,685
278,344
252,221
193,617
233,172
216,137
216,137233,172193,617252,221278,344246,685264,455243,022119,543179,959144,91247,9643,21208,11413,45428,23946,82715,93511,18522,05438,53261,38772,753
       Net Receivables 
5,002
3,602
3,598
22,146
5,642
3,997
5,422
8,646
18,386
27,620
26,212
29,413
36,415
41,491
42,610
50,599
48,639
57,667
53,646
56,950
60,586
68,759
72,456
79,069
79,06972,45668,75960,58656,95053,64657,66748,63950,59942,61041,49136,41529,41326,21227,62018,3868,6465,4223,9975,64222,1463,5983,6025,002
       Inventory 
600
1,000
1,776
0
0
5,233
6,241
7,039
5,113
9,846
13,663
15,791
16,144
23,378
27,019
27,533
27,466
27,033
29,630
28,683
29,781
4,450
7,562
8,087
8,0877,5624,45029,78128,68329,63027,03327,46627,53327,01923,37816,14415,79113,6639,8465,1137,0396,2415,233001,7761,000600
   > Long-term Assets 
24,689
12,625
11,697
10,937
11,081
10,869
13,790
10,915
10,660
11,482
13,020
22,015
16,006
15,685
49,593
33,500
18,854
18,829
20,458
20,994
20,792
108,962
64,129
68,452
68,45264,129108,96220,79220,99420,45818,82918,85433,50049,59315,68516,00622,01513,02011,48210,66010,91513,79010,86911,08110,93711,69712,62524,689
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,261
8,617
15,422
15,384
20,458
20,914
7,831
7,663
7,421
19,785
19,7857,4217,6637,83120,91420,45815,38415,4228,61715,26100000000000000
       Long Term Investments 
11,655
741
0
0
0
0
3,002
0
0
0
0
6,829
0
0
34,332
18,077
3,432
3,445
0
0
0
64,317
19,426
20,323
20,32319,42664,3170003,4453,43218,07734,332006,82900003,002000074111,655
       Long-term Assets Other 
5,390
4,333
4,245
3,590
3,811
3,720
3,646
3,802
0
0
0
6,472
0
0
0
6,806
0
0
0
80
12,961
36,982
37,282
28,344
28,34437,28236,98212,961800006,8060006,4720003,8023,6463,7203,8113,5904,2454,3335,390
> Total Liabilities 
119,831
125,537
131,753
137,030
132,941
138,199
142,589
353,977
359,419
383,359
412,807
695,137
691,935
723,770
801,253
844,597
838,024
918,598
933,910
972,488
944,059
948,025
959,817
966,354
966,354959,817948,025944,059972,488933,910918,598838,024844,597801,253723,770691,935695,137412,807383,359359,419353,977142,589138,199132,941137,030131,753125,537119,831
   > Total Current Liabilities 
66,326
71,948
82,169
92,335
92,699
102,650
111,777
105,654
101,201
115,601
133,608
103,718
81,017
95,390
81,637
105,514
85,157
93,498
90,763
149,988
119,921
129,065
153,567
160,384
160,384153,567129,065119,921149,98890,76393,49885,157105,51481,63795,39081,017103,718133,608115,601101,201105,654111,777102,65092,69992,33582,16971,94866,326
       Short-term Debt 
29,231
29,341
33,487
38,581
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000038,58133,48729,34129,231
       Short Long Term Debt 
29,231
29,341
33,487
38,581
43,697
48,836
49,038
30,000
30,000
30,000
30,000
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000030,00030,00030,00030,00049,03848,83643,69738,58133,48729,34129,231
       Accounts payable 
6,935
8,298
10,084
13,988
10,061
9,354
11,616
18,713
13,529
10,087
19,693
27,808
13,881
12,024
8,622
14,356
6,254
13,889
10,567
20,893
11,910
7,786
13,482
11,644
11,64413,4827,78611,91020,89310,56713,8896,25414,3568,62212,02413,88127,80819,69310,08713,52918,71311,6169,35410,06113,98810,0848,2986,935
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,565
26,022
28,974
33,000
32,676
32,67633,00028,97426,02223,5650000000000000000000
   > Long-term Liabilities 
53,505
53,589
49,584
44,695
40,242
35,549
30,812
248,323
258,218
267,758
279,199
591,419
610,918
628,380
719,616
739,083
752,867
825,100
843,147
822,500
824,138
818,960
806,250
805,970
805,970806,250818,960824,138822,500843,147825,100752,867739,083719,616628,380610,918591,419279,199267,758258,218248,32330,81235,54940,24244,69549,58453,58953,505
       Long term Debt 
49,616
49,847
46,041
41,289
36,513
31,715
26,893
244,452
123,039
126,796
132,050
585,457
604,461
144,516
713,648
733,279
746,933
819,297
833,181
811,265
813,036
808,481
796,108
795,922
795,922796,108808,481813,036811,265833,181819,297746,933733,279713,648144,516604,461585,457132,050126,796123,039244,45226,89331,71536,51341,28946,04149,84749,616
       Capital Lease Obligations 
0
3,742
4,995
4,783
5,030
4,930
4,844
5,050
4,884
5,081
6,487
7,781
8,538
8,332
8,164
8,173
8,425
8,333
12,248
13,883
13,842
13,186
13,030
12,820
12,82013,03013,18613,84213,88312,2488,3338,4258,1738,1648,3328,5387,7816,4875,0814,8845,0504,8444,9305,0304,7834,9953,7420
       Long-term Liabilities Other 
3,889
0
0
0
0
0
0
0
131,296
136,862
142,114
0
0
477,666
0
0
0
0
0
0
0
0
0
0
0000000000477,66600142,114136,862131,29600000003,889
> Total Stockholder Equity
22,507
-9,193
-41,253
38,252
3,648
76,507
33,637
-19,262
-74,988
-106,075
-147,044
-106,986
-1,281,700
-1,340,559
-1,383,079
-294,597
-328,287
-388,713
-410,986
-455,528
-476,167
-475,606
-468,563
-475,934
-475,934-468,563-475,606-476,167-455,528-410,986-388,713-328,287-294,597-1,383,079-1,340,559-1,281,700-106,986-147,044-106,075-74,988-19,26233,63776,5073,64838,252-41,253-9,19322,507
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue450,712
Cost of Revenue-12,485
Gross Profit438,227438,227
 
Operating Income (+$)
Gross Profit438,227
Operating Expense-453,255
Operating Income-2,543-15,028
 
Operating Expense (+$)
Research Development174,638
Selling General Administrative266,132
Selling And Marketing Expenses0
Operating Expense453,255440,770
 
Net Interest Income (+$)
Interest Income14,746
Interest Expense-98,516
Other Finance Cost-0
Net Interest Income-83,770
 
Pretax Income (+$)
Operating Income-2,543
Net Interest Income-83,770
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-86,954-1,902
EBIT - interestExpense = -98,516
-88,881
9,635
Interest Expense98,516
Earnings Before Interest and Taxes (EBIT)011,562
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-86,954
Tax Provision-1,927
Net Income From Continuing Ops-88,881-88,881
Net Income-88,881
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-64183,770
 

Technical Analysis of BIOCRYST PHARM (BO1.SG)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BIOCRYST PHARM (BO1.SG). The general trend of BIOCRYST PHARM (BO1.SG) is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BIOCRYST PHARM (BO1.SG)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BIOCRYST PHARM (BO1.SG).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.298 < 9.006.

The bearish price targets are: 6.588 > 6.466 > 6.438.

Tweet this
BIOCRYST PHARM (BO1.SG) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BIOCRYST PHARM (BO1.SG). The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BIOCRYST PHARM (BO1.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Moving Average Convergence/Divergence (MACD) ChartBIOCRYST PHARM (BO1.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BIOCRYST PHARM (BO1.SG). The current adx is .

BIOCRYST PHARM (BO1.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Relative Strength Index (RSI) ChartBIOCRYST PHARM (BO1.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Stochastic Oscillator ChartBIOCRYST PHARM (BO1.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Commodity Channel Index (CCI) ChartBIOCRYST PHARM (BO1.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Chande Momentum Oscillator (CMO) ChartBIOCRYST PHARM (BO1.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Williams %R ChartBIOCRYST PHARM (BO1.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Average True Range (ATR) ChartBIOCRYST PHARM (BO1.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily On-Balance Volume (OBV) ChartBIOCRYST PHARM (BO1.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BIOCRYST PHARM (BO1.SG).

BIOCRYST PHARM (BO1.SG) Daily Money Flow Index (MFI) ChartBIOCRYST PHARM (BO1.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BIOCRYST PHARM (BO1.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

BIOCRYST PHARM (BO1.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BIOCRYST PHARM (BO1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose6.910
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of BIOCRYST PHARM (BO1.SG) with someone you think should read this too:
  • Are you bullish or bearish on BIOCRYST PHARM (BO1.SG)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BIOCRYST PHARM (BO1.SG)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BIOCRYST PHARM (BO1.SG)

I send you an email if I find something interesting about BIOCRYST PHARM (BO1.SG).


Comments

How you think about this?

Leave a comment

Stay informed about BIOCRYST PHARM (BO1.SG).

Receive notifications about BIOCRYST PHARM (BO1.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.